Gout Medicine May Help Fight This Disease - medtigo


Gout Medicine May Help Fight This Disease

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

According to experts, the anti-inflammatory properties of a common gout drug may help save the lives of heart failure patients. 

According to the study authors, the drug colchicine may lessen the risk of heart attack and stroke in patients with cholesterol-clogged arteries. 

“The signal for benefit with colchicine in these patients was very impressive,” Dr. Kenneth Bilchick said in a University of Virginia (UVA) news release. “I expect that these findings will have quite a significant impact on clinical care in heart failure and future research for patients with this condition.” He teaches cardiovascular medicine at the university. 

Bilchick and his colleagues looked at the data of over 1,000 patients admitted to the university’s Medical Center for worsening heart failure between March 2011 and February 2020. Heart failure happens when the heart can’t pump enough blood through the body. 

Those who received colchicine for a gout flare had a survival rate of about 98 percent, compared to fewer than 94 percent for those who did not receive colchicine. 

Gout is a kind of arthritis characterized by a buildup of uric acid crystals in the joints that affects many patients with heart failure. 


As per US News, colchicine, steroids, and nonsteroidal anti-inflammatory medications (NSAIDs) like aspirin and ibuprofen are all common gout therapies. However, because steroids and nonsteroidal anti-inflammatory drugs (NSAIDs) can exacerbate heart failure symptoms, they are rarely prescribed to heart failure patients. 

According to the experts, colchicine may help heart failure patients by lowering inflammation in the heart and blood arteries. 

While larger studies are needed to confirm these preliminary findings, the research team believes they are promising. 

“These findings emphasize the significance of novel inflammatory processes in heart failure,” said Bilchick. 

According to Dr. Sula Mazimba, a cardiologist and researcher at the University of Virginia School of Medicine, heart failure is more than just a loss of the heart’s pumping function. “Other processes, including as increased inflammation and neuro-hormonal processes, are involved, especially during the acute hospitalization phase. Many heart failure drugs target neuro-hormonal pathways, while very few, if any, target inflammatory pathways “Mazimba said. 

“Colchicine is an anti-inflammatory medicine that could potentially reduce the increased inflammation seen in individuals with heart failure who are hospitalized,” Mazimba explained. 

According to the American Heart Association, heart failure affects around 6 million Americans and causes more than 86,000 deaths each year. 

The outcomes of the study were just published in the journal Clinical Cardiology. 

Leave a Reply